307 related articles for article (PubMed ID: 4045923)
41. Arginine-vasopressin analogues with high antidiuretic/vasopressor selectivity. Synthesis, biological activity, and receptor binding affinity of arginine-vasopressin analogues with substitutions in positions 1, 2, 4, 7, and 8.
Grzonka Z; Kasprzykowski F; Kojro E; Darlak K; Melin P; Fahrenholz F; Crause P; Boer R
J Med Chem; 1986 Jan; 29(1):96-9. PubMed ID: 2416923
[TBL] [Abstract][Full Text] [Related]
42. Position 4 analogues of [deamino-Cys(1)] arginine vasopressin exhibit striking species differences for human and rat V(2)/V(1b) receptor selectivity.
Guillon G; Pena A; Murat B; Derick S; Trueba M; Ventura MA; Szeto HH; Wo N; Stoev S; Cheng LL; Manning M
J Pept Sci; 2006 Mar; 12(3):190-8. PubMed ID: 16130178
[TBL] [Abstract][Full Text] [Related]
43. Further in vivo evidence for antagonist-to-antidiuretic action of arginine vasopressin.
Ishikawa S; Kim JK; Schrier RW
Am J Physiol; 1983 Nov; 245(5 Pt 1):R713-9. PubMed ID: 6688929
[TBL] [Abstract][Full Text] [Related]
44. Synthesis, antidiuretic and pressor activities of [arginine4]arginine-vasopressin and two related analogues.
Rekowski P; Lammek B; Melin P; Ragnarsson U; Kupryszewski G
Acta Chem Scand B; 1985; 39(6):453-7. PubMed ID: 4060959
[TBL] [Abstract][Full Text] [Related]
45. [1-beta-Mercapto-beta,beta-cyclopentamethylenepropionic acid),2-(O-methyl)tyrosine ]argine-vasopressin and [1-beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)]argine-vasopressine, two highly potent antagonists of the vasopressor response to arginine-vasopressin.
Kruszynski M; Lammek B; Manning M; Seto J; Haldar J; Sawyer WH
J Med Chem; 1980 Apr; 23(4):364-8. PubMed ID: 6892930
[No Abstract] [Full Text] [Related]
46. Influence of enantiomers of 1-naphthylalanine in position 2 of VAVP and dVAVP on their pharmacological properties.
Derdowska I; Prahl A; Kowalczyk W; Janecki M; Melhem S; Trzeciak HI; Lammek B
Eur J Med Chem; 2005 Jan; 40(1):63-8. PubMed ID: 15642410
[TBL] [Abstract][Full Text] [Related]
47. Potent V2 vasopressin antagonists with structural changes at their C-terminals.
Sawyer WH; Bankowski K; Misicka A; Nawrocka E; Kruszynski M; Stoev S; Klis WA; Przybylski JP; Manning M
Peptides; 1988; 9(1):157-63. PubMed ID: 3362743
[TBL] [Abstract][Full Text] [Related]
48. Hemodynamic effects of antagonists of the vasoconstrictor action of vasopressin in conscious dogs.
Liard JF; Spadone JC
J Cardiovasc Pharmacol; 1984; 6(4):713-9. PubMed ID: 6206331
[TBL] [Abstract][Full Text] [Related]
49. Analogues of arginine vasopressin modified in position 2 or 3 with naphthylalanine: selective antagonists of oxytocin in-vitro.
Sobocińska M; Lempicka E; Konieczna E; Derdowska I; Lammek B; Melhem S; Kozik W; Janecka J; Janecki M; Trzeciak HI
J Pharm Pharmacol; 2000 Sep; 52(9):1105-12. PubMed ID: 11045891
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of vasopressin-stimulated flank marking behavior by V1-receptor antagonists.
Ferris CF; Singer EA; Meenan DM; Albers HE
Eur J Pharmacol; 1988 Sep; 154(2):153-9. PubMed ID: 2976377
[TBL] [Abstract][Full Text] [Related]
51. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
Cheng LL; Stoev S; Manning M; Derick S; Pena A; Mimoun MB; Guillon G
J Med Chem; 2004 Apr; 47(9):2375-88. PubMed ID: 15084136
[TBL] [Abstract][Full Text] [Related]
52. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Pena A; Murat B; Trueba M; Ventura MA; Wo NC; Szeto HH; Cheng LL; Stoev S; Guillon G; Manning M
J Med Chem; 2007 Feb; 50(4):835-47. PubMed ID: 17300166
[TBL] [Abstract][Full Text] [Related]
53. Surprising pharmacological activity of analogues designed by substitution of position 3 in arginine vasopressin (AVP) and 8-D-arginine vasopressin with L-2-napthylalanine.
Lammek B; Konieczna E; Trzeciak HI; Kozłowski A; Szymkowiak J; Stojko R; Kupryszewski G
J Pharm Pharmacol; 1996 Mar; 48(3):316-9. PubMed ID: 8737061
[TBL] [Abstract][Full Text] [Related]
54. Novel linear antagonists of the antidiuretic (V2) and vasopressor (V1) responses to vasopressin.
Manning M; Klis WA; Kruszynski M; Przybylski JP; Olma A; Wo NC; Pelton GH; Sawyer WH
Int J Pept Protein Res; 1988 Dec; 32(6):455-67. PubMed ID: 3246475
[TBL] [Abstract][Full Text] [Related]
55. Evidence for independent actions of vasopressin on renal inner medullary cyclic AMP and prostaglandin E production: relationship of the prostaglandin E response to hormone pressor activity.
Campbell HT; Craven PA; DeRubertis FR
Metabolism; 1982 Oct; 31(10):1035-41. PubMed ID: 6290836
[TBL] [Abstract][Full Text] [Related]
56. Properties of a new radioiodinated antagonist for human vasopressin V2 and V1a receptors.
Ala Y; Morin D; Mahé E; Cotte N; Mouillac B; Jard S; Barberis C; Tribollet E; Dreifuss JJ; Sawyer WH; Wo NC; Chan WY; Kolodziejczyk AS; Cheng LL; Manning M
Eur J Pharmacol; 1997 Jul; 331(2-3):285-93. PubMed ID: 9274991
[TBL] [Abstract][Full Text] [Related]
57. Enhanced selectivity of oxytocin antagonists containing sarcosine in position 7.
Pavo I; Slaninova J; Klein U; Fahrenholz F
J Med Chem; 1994 Jan; 37(2):255-9. PubMed ID: 7507528
[TBL] [Abstract][Full Text] [Related]
58. Prostaglandin E2 and cyclic AMP response to vasopressin in renal medullary tubular cells.
Wuthrich RP; Vallotton MB
Am J Physiol; 1986 Sep; 251(3 Pt 2):F499-505. PubMed ID: 3019160
[TBL] [Abstract][Full Text] [Related]
59. Analogues of arginine vasopressin modified in position 2 and 3 with conformationally constrained dipeptide fragments.
Łempicka E; Derdowska I; Kowalczyk W; Dawidowska O; Prahl A; Janecki M; Jasiński T; Trzeciak HI; Lammek B
J Pept Sci; 2005 Feb; 11(2):91-6. PubMed ID: 15635636
[TBL] [Abstract][Full Text] [Related]
60. Characterization of human platelet vasopressin receptors.
Thibonnier M; Roberts JM
J Clin Invest; 1985 Nov; 76(5):1857-64. PubMed ID: 2997293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
